Latest news with #Myota
Yahoo
10 hours ago
- Business
- Yahoo
Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category
BOSTON, June 18, 2025 /PRNewswire/ -- Lindus Health, the anti-CRO running radically faster, more reliable clinical trials, has been honored the winner in the 2025 Fierce CRO Awards' Outstanding Patient Recruitment and Retention category, which celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards spotlight CROs that exemplify innovation, performance, and leadership in advancing life sciences research and improving patient outcomes. Lindus Health earned this recognition for its innovative use of the Patient Identification Center (PIC) technique, which leverages advanced algorithms and customized search protocols based on real-world medical record data to reduce screen fail rates and accelerate recruitment with greater precision. This approach was instrumental in its collaboration with Myota on a pre-diabetes trial, which achieved a 54% screening conversion rate—five times the industry benchmark—and completed enrollment in just four months. Backed by deep expertise in healthcare data, clinical systems, and physician behavior, Lindus Health's unique PIC approach stands out not just for using EHR-driven participant searches, but for how it executes them. While many CROs rely on medical practices to run standard queries, Lindus builds its own highly customized, in-house searches. These go beyond basic inclusion and exclusion criteria, incorporating a nuanced understanding of how data is actually recorded and coded by general practitioners. For example, when a trial sought patients with "reduced sexual desire," Lindus optimized results by using "low libido"—a term more commonly coded by GPs—significantly improving the ability to identify eligible participants. "Receiving the Fierce CRO Award is a tremendous honor," said Meri Beckwith, co-founder of Lindus Health. "It reflects our mission to fix the broken clinical trial model so patients can access treatments faster. With innovative strategies like our PIC technique, smart study design, and proprietary AI, we're delivering faster, more precise, and cost-effective trials—even in complex cases. Our work isn't done though, and we're continuing to push the boundaries of what's possible in clinical research, making it more efficient, inclusive, and patient-centric every step of the way." This award comes on the heels of Lindus Health's Series B funding round of $55 million, which is fueling strategic hiring across clinical operations and product development, while expanding the capabilities of its proprietary AI-powered eClinical platform, Citrus™. The investment is enabling advancements in study design optimization, automated central monitoring, and real-time biostatistics. As the only major service provider with a fully in-house platform, Lindus integrates all core clinical research technologies—including CTMS, EDC, eDiary, visit scheduling, and more—into a seamless, unified ecosystem. In partnership with Oxford University, Lindus Health published a study on diverse perceptions of clinical trial participation, helping to inform more inclusive and patient-centered research. Additionally, Lindus is collaborating with CDISC, the organization that sets clinical data standards for the FDA, to develop standardized templates for clinical observations and is contributing to ARIA's Safeguarded AI program to improve trial design through safer, more reliable AI. The full Fierce CRO Awards report profiling all winners is available here. Lindus Health's award-winning capabilities can be found at About Lindus Health Lindus Health is an anti-CRO running radically faster, more reliable clinical trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 40 million Electronic Health Records. Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint through end-to-end execution of clinical studies driven by technology and forward-thinking approaches to clinical operations. To date, Lindus Health has delivered clinical trials across the US, UK, and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum, Firstminute Capital, and Seedcamp. About Fierce BiotechFierce Biotech is the biotech industry's daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free here. Press contact: Jodi PerkinsAmendola Communications for Lindus HealthJperkins@ Cell: 847.508.0877 View original content to download multimedia: SOURCE Lindus Health
Yahoo
13-05-2025
- Business
- Yahoo
SUANNUTRA and Myota Partner to Deliver Precision Prebiotic Solutions Across US, UK, and EU
Myota's Metabolic Regulator offers precision-formulated, science-backed prebiotic fibers to support healthy metabolism BARCELONA, Spain, May 13, 2025 /PRNewswire/ -- SUANNUTRA, a global leader in nutraceutical ingredients, has entered an exclusive distribution agreement with UK-based Myota to launch its clinically backed prebiotic fiber blends—including the flagship Metabolic Regulator—across the US, UK, and EU[1]. At the heart of this collaboration lies a powerful scientific synergy: Myota's patented blend of nine plant-based fibres promotes the direct production of beneficial short-fatty acids (SCFAs) through targeted fermentation by gut microbiota. SUANNUTRA's flagship ingredient, Metabolaid®, complements this effect by indirectly supporting SCFA generation via microbiome modulation. These SCFAs play a key role in the stimulation of GLP-1. In addition, Metabolaid® activates AMPK pathway and helping maintain healthy lipid metabolism and blood pressure levels. Together, these technologies deliver a synergistic, multi-pathway approach to metabolic health - enhancing prebiotic action at the gut level and supporting systemic metabolic balance. Metabolic Regulator has been studied for supporting healthy blood sugar levels, maintaining cholesterol already within a normal range, and minimising postprandial glucose spikes with evidence drawn from MIT research and third-party clinical trials. Its low-FODMAP, clean-label formulation is suitable even for those with digestive sensitivities. "This partnership enhances our portfolio with targeted microbiome-nourishing solutions, providing next-gen support for cardiometabolic wellness," said Anthony Weston, CEO of SUANNUTRA. "By combining Metabolaid®'s support of key metabolic pathways with Myota's microbiome-driven prebiotic approach, we're delivering a complementary dual-action approach to today's metabolic health needs." Thomas Gurry, PhD, CEO of Myota, added: "We see immense value in pairing our fermentation-optimized prebiotics with SUANNUTRA's clinically vetted actives. Together, we are shifting the paradigm from generic gut health to precision-formulated, systemic wellness." The full range, including blends for immune and digestive health, will debut at Vitafoods Europe 2025 (May 20–22, Booth #3K22). Custom blends and formulation support will also be available through SUANNUTRA. About SUANNUTRA and Myota About SUANNUTRA SUANNUTRA is a Global leading nutraceutical ingredient player, offering a growing portfolio of scientifically backed, clinically proven branded & functional ingredient sourcing. SUANNUTRA boasts more than 22 clinical studies, and 6 awards won across a proprietary and scientifically endorsed, branded ingredients portfolio addressing the Weight Management, Beauty from Within and Women's Health segments, by leveraging innovative science and underpinned by a strong pipeline. About Myota Founded in 2019, Myota develops clean-label, low-FODMAP prebiotic blends grounded in nearly a decade of research at MIT. Focused on tailoring fiber blends to individual microbiome profiles, Myota ensures maximum fermentation efficiency and clinical efficacy—bridging gut and metabolic health. 1. Excludes Germany and Austria. Photo: For more information, please contact: SUANNUTRAWebsite: info@ MyotaWebsite: info@ Press ContactNutriPRLiat Simha Email: liat@ Tel.: +972-9-9742893 View original content to download multimedia: SOURCE SUANNUTRA; Myota Sign in to access your portfolio
